X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SUN PHARMA 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 18th October, 2018 on account of Dussehra.

SUN PHARMA 2017-18 Annual Report Analysis
Wed, 19 Sep

SUN PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

SUN PHARMA Income Statement Analysis

  • Operating income during the year fell 16.1% on a year-on-year (YoY) basis.
  • The company's operating profit decreased by 44.4% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 21.2% in FY18 as against 31.9% in FY17.
  • Depreciation charges and finance costs increased by 18.6% YoY and 29.5% YoY, respectively.
  • Other income grew by 34.6% YoY.
  • Net profit for the year declined by 66.4% YoY.
  • Net profit margins during the year declined from 24.3% in FY17 to 9.6% in FY18.

SUN PHARMA Income Statement 2017-18

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Net Sales Rs m 315,784 264,895 -16.1%
Other income Rs m 6,232 8,388 34.6%
Total Revenues Rs m 322,016 273,282 -15.1%
Gross profit Rs m 100,893 56,081 -44.4%
Depreciation Rs m 12,648 14,998 18.6%
Interest Rs m 3,998 5,176 29.5%
Profit before tax Rs m 90,479 44,295 -51.0%
Tax Rs m 12,116 8,452 -30.2%
Profit after tax Rs m 78,363 26,338 -66.4%
Gross profit margin % 31.9 21.2
Effective tax rate % 13.4 19.1
Net profit margin % 24.3 9.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



SUN PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 199 billion as compared to Rs 179 billion in FY17, thereby witnessing an increase of 11.1%.
  • Long-term debt stood at Rs 18 billion as compared to Rs 14 billion during FY17, a growth of 23.4%.
  • Current assets fell 4% and stood at Rs 316 billion, while fixed assets rose 4% and stood at Rs 213 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 643 billion as against Rs 614 billion during FY17, thereby witnessing a growth of 5%.

SUN PHARMA Balance Sheet as on March 2018

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Networth Rs m 366,397 381,006 4.0
 
Current Liabilities Rs m 178,870 198,643 11.1
Long-term Debt Rs m 14,361 17,721 23.4
Total Liabilities Rs m 614,102 643,028 4.7
 
Current assets Rs m 329,537 316,359 -4.0
Fixed Assets Rs m 204,766 213,178 4.1
Total Assets Rs m 614,102 643,028 4.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



SUN PHARMA Cash Flow Statement Analysis

  • SUN PHARMA's cash flow from operating activities (CFO) during FY18 stood at Rs 39 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -34 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs -15 billion, an improvement of 33% on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -7 billion from the Rs 6 billion net cash flows seen during FY17.

SUN PHARMA Cash Flow Statement 2017-18

Particulars No. of months 12 12 % Change
Year Ending Mar-17 Mar-18
Cash Flow from Operating Activities Rs m 70,822 39,072 -44.8%
Cash Flow from Investing Activities Rs m -42,216 -33,708 -
Cash Flow from Financing Activities Rs m -22,854 -15,393 -
Net Cash Flow Rs m 6,107 -7,359 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for SUN PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 11.0, an decline from the EPS of Rs 32.7 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 646.5, stands at 38.3 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.6 times, while the price to sales ratio stands at 5.1 times.
  • The company's price to cash flow (P/CF) ratio stood at 37.6 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Sales per share (Unadj.) Rs 131.6 110.4
TTM Earnings per share Rs 32.7 11.0
Diluted earnings per share Rs 32.6 10.9
Price to Cash Flow x 17.0 37.6
TTM P/E ratio x 38.2 38.3
Price / Book Value ratio x 4.6 3.6
Market Cap Rs m 1,551,122 1,555,966
Dividends per share (Unadj.) Rs 3.5 2.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for SUN PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.6x during FY18, from 1.8x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 9.6x during FY18, from 23.6x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 6.9% during FY18, from 21.4% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 10.0% during FY18, from 24.8% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 4.9% during FY18, from 13.4% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Current ratio x 1.8 1.6
Debtors’ Days Days 83 108
Interest coverage x 23.6 9.6
Debt to equity ratio x 0.0 0.0
Return on assets % 13.4 4.9
Return on equity % 21.4 6.9
Return on capital employed % 24.8 10.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how SUN PHARMA has performed over the last 5 years, please visit here.

SUN PHARMA Share Price Performance

Over the last one year, SUN PHARMA share price has moved up from Rs 516.6 to Rs 646.5, registering a gain of Rs 129.9 or around 25.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 15,959.5 (up 0.1%). Over the last one year it has moved up from 13,744.7 to 15,959.5, a gain of 2,215 points (up 16.1%).

Overall, the S&P BSE SENSEX is up 15.2% over the year.

(To know more, check out historical annual results for SUN PHARMA and quarterly results for SUN PHARMA)

Equitymaster requests your view! Post a comment on "SUN PHARMA 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS